Loading company…
Zenas BioPharma develops immunology-based therapies for autoimmune diseases.
Founded in 2019 by Lonnie Moulder Jr and based in Massachusetts, Zenas BioPharma is a clinical-stage company developing therapies for autoimmune diseases. In May 2024, it raised USD 200.15 million in Series C funding co-led by SR One, New Enterprise Associates, Norwest Venture Partners, and Delos Capital Partners, among others. Its lead candidate, obexelimab, is being developed for mid- to late-stage clinical trials. The company completed an IPO in September 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in